Please use this identifier to cite or link to this item: https://repositorio.unifesp.br/handle/11600/29321
Title: Randomized controlled trial of FTY720 versus MMF in de novo renal transplantation
Authors: Tedesco-Silva, Helio
Pescovitz, Mark D.
Cibrik, Diane
Rees, Michael A.
Mulgaonkar, Shamkant
Kahan, Barry D.
Gugliuzza, Kristene K.
Rajagopalan, P. R.
Esmeraldo, Ronaldo de M.
Lord, Helene
Salvadori, Maurizio
Slade, Jennifer M.
FTY720 Study Grp
Universidade Federal de São Paulo (UNIFESP)
Indiana Univ
Univ Michigan
Univ Toledo
St Barnabas Hosp
Univ Texas
Med Univ S Carolina
Hosp Geral Fortaleza
Hop Maison Neuve Rosemont
Careggi Univ Hosp
Novartis Pharmaceut Corp
Keywords: FTY720
mycophenolate mofetil
renal transplantation
cyclosporine
sphingosine inhibitors
Issue Date: 27-Dec-2006
Publisher: Lippincott Williams & Wilkins
Citation: Transplantation. Philadelphia: Lippincott Williams & Wilkins, v. 82, n. 12, p. 1689-1697, 2006.
Abstract: Background. Phase 11 trials of FTY720, a novel immunomodulator, have shown promise in preventing rejection with both standard and reduced cyclosporine exposure. This study was designed to confirm those findings.Methods. This one-year, multicenter, randomized, phase III study in 696 de novo renal transplant patients compared FTY720 5 mg plus reduced-dose cyclosporine (RDC) or FTY720 2.5 mg plus full-dose cyclosporine (FDC) with mycophenolate mofetil (MMF) plus FDC. All patients received concomitant corticosteroid therapy without antibody induction. the primary efficacy composite endpoint was the incidence of first treated biopsy-proven acute rejection (treated BPAR), graft loss, death or premature study discontinuation at month 12.Results. FTY720 2.5 mg plus FDC was demonstrated to be non-inferior to MMF plus FDC as the primary efficacy endpoint (30.8% and 30.6%) was comparable. the FTY720 5 mg plus RDC treatment regimen was discontinued due to an increased incidence of acute rejection episodes (primary endpoint 43.3%). FTY720 was associated with significantly lower creatinine clearance with a mean difference at 12 months between FTY720 2.5 mg plus FDC and MMF plus FDC of 8 ml/min.Conclusions. While FTY720 2.5 mg plus FDC yielded similar efficacy to MMF plus FDC, the FTY720 5 mg plus RDC did not allow a 50% reduction in cyclosporine exposure. the associated lower creatinine clearance indicated that FTY720 combined with cyclosporine provided no benefit over standard care.
URI: http://repositorio.unifesp.br/handle/11600/29321
ISSN: 0041-1337
Other Identifiers: http://dx.doi.org/10.1097/01.tp.0000251718.95622.b3
Appears in Collections:Em verificação - Geral

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.